Clinical trials: Alzheimer Disease 3
Transthyretin (TTR) Amyloid Cardiomyopathy
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
- Trial name
- NCT02791230
- Testing
- Tafamidis
- Where
- 80 sites in United States, Argentina and 15 more
- Volunteers
- 1,733 people
- Sponsor
- Pfizer
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer's Disease, Mild Cognitive Impairment
System-IGF-1 Pathway and Alzheimer's Disease
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Cognitive Function 1, Social, Control With Normal Activities of Daily Living
- Trial name
- SIGAL (NCT00647478)
- Where
- France
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neurodegenerative Diseases, Parkinson Disease
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
Personalized Integrated Care Promoting Quality of Life for Elderly People (ProCare4Life, PC4L) project was created to finalize a digital platform with integrated sensors , for monitoring the health status of the elderly subjects…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease, Quality of Life
- Trial name
- NCT05538455
- Testing
- PC4L solutions
- Where
- Italy
- Volunteers
- 558 people
- Sponsor
- Casa di Cura Privata del Policlinico SpA
Alzheimer´s Disease
Phase 3 IGIV, 10% in Alzheimer´s Disease
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
- Trial name
- NCT01524887
- Testing
- Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
- Where
- 69 sites in United States, Australia and 6 more
- Volunteers
- 508 people
- Sponsor
- Baxalta now part of Shire
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Agitation, Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
- Trial name
- NCT06808984
- Testing
- BMS-986368
- Where
- 77 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Celgene
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Trial name
- NCT03548584
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer Disease
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810).
- Trial name
- NCT00996918
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 82 sites in Australia, Belgium and 15 more
- Volunteers
- 198 people
- Sponsor
- Pfizer
Alzheimer Disease
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
This is a 24-week prospective, randomized, double-blind, placebo-controlled, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate…
- Trial name
- DOPAD-3 (NCT06702124)
- Testing
- Rotigotine 4Mg/24Hrs Patch
- Where
- Italy
- Volunteers
- 348 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Alzheimer Disease
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
- Trial name
- NCT00151398
- Testing
- lecozotan SR, Donepezil
- Where
- 56 sites in United States, Argentina and 3 more
- Volunteers
- 229 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease, Central Nervous System Diseases
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are…
- Trial name
- NCT00766363
- Testing
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Conditions
- Alzheimer Disease, Dementia, Plaque, Amyloid
- Trial name
- NCT07602582
- Testing
- Donanemab
- Where
- 62 sites in United States, Japan and 1 more
- Volunteers
- 550 people
- Sponsor
- Eli Lilly and Company
Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04464564
- Testing
- AVP-786
- Where
- 106 sites in United States, Belgium and 11 more
- Volunteers
- 241 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment.
- Trial name
- Identity XT (NCT01035138)
- Testing
- semagacestat
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose…
- Trial name
- R2 (NCT02359552)
- Testing
- Rasagiline
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Mild to Moderate Alzheimer's Disease
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ROBIN (NCT01039701)
- Testing
- AZD1446
- Where
- 12 sites in Czechia, Hungary and 1 more
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb